secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001683168-23-003210
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sunshine Biopharma reports Q1 2023 revenues of $4.89M, up 2,100% YoY
--------------------------------------------------------------------

- Gross revenues of $4,894,053 for Q1 2023, a 2,100% increase over Q1 2022, driven by Nora Pharma acquisition.
- Repurchased 445,711 common shares under $2M stock buyback program; shares cancelled, reducing outstanding count to 22,139,921.
- Entered research agreement with Jewish General Hospital to advance Adva-27a anticancer compound through IND-enabling studies.
- Obtained exclusive worldwide license from University of Arizona for PLpro protease inhibitors of SARS-CoV-2 (COVID-19).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316823003210/0001683168-23-003210-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316823003210/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-003210

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer